In HER2-positive early breast cancer, Kadcyla shows sustained improvement in both invasive disease-free survival and overall survival versus Herceptin.
Dr. Charles E. Geyer
Advertisement
Dr. Charles E. Geyer is a professor of medicine at the University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center and UPMC Magee-Womens Hospital, in Pittsburgh, as well as the chief scientific officer at the National Surgical Adjuvant Breast and Bowel Project (NSABP) Foundation.
Articles by Dr. Charles E. Geyer
Antibody-drug conjugates have had a tremendous impact on breast cancer care and treatment, according to Dr. Charles E. Geyer.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
